Comment from Zydus Lifesciences Limited

Summary: Zydus Lifesciences Limited supports the SUPAC guidances as a critical framework but recommends updates to modernize them, reduce ambiguity, and align them with current scientific knowledge and ICH standards. They specifically advocate for consolidating overarching principles into a unified guidance, providing clearer risk-based decision frameworks, and developing new guidance for complex dosage forms.